3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
3
Phase 2/3
1
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Ameloblastoma
1
Interventions
Dexamethasone
8
daratumumab
5
Lenalidomide
5
Bortezomib
5
Thalidomide
4
Cyclophosphamide
4
carfilzomib
2
Melphalan
2
Calcium Dobesilate
2
trametinib
1
tanespimycin
1
pomalidomide
1
fludarabine
1
dabrafenib
1
cobimetinib
1
Whole-Body Irradiation
1
Vemurafenib
1
Stem Cell Transplantation
1
Rivaroxaban
1
Mesna
1
MAGEA3 protein, human
1
Lenograstim
1
Human Growth Hormone
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Etoposide
1
Busulfan
1
Bone Marrow Transplantation
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Multiple Myeloma
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled